For more than a century, heparin has been the go-to anticoagulant to prevent harmful blood clots in blood vessels or the heart from forming or getting larger. However, a major side effect is an ...

The heparin market is projected to grow at a CAGR of 7.02% during 2027–2032. Asia-Pacific leads the market, while growing interest in biosynthetic alternatives and diversified raw material sources is ...

Heparin, a drug traditionally injected to treat blood clots, was tested in this study in an inhaled form, targeting the lungs directly. As well as acting as an anticoagulant, heparin has ...

Therapeutic-dose heparin appears to benefit noncritically-ill COVID-19 patients, but it does not reduce deaths or other adverse endpoints compared with usual-care thromboprophylaxis if it’s initiated ...

New research reveals that patients receiving heparin therapy were diagnosed with Alzheimer's disease up to two years later, suggesting a possible protective effect of this common anticoagulant. Study: ...

A case report describes how a 10-year-old girl with protein S deficiency survived a massive pulmonary embolism on ECMO using ...

Each month, our three presenters will review an interesting journal article in a conversational manner. These articles will involve “hot topics” that affect family physicians or will “bust” commonly ...

Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the most serious type of heart attacks who undergo urgent percutaneous coronary intervention (PCI), and ...

Now reported in the Journal are the results of an international, multiplatform, randomized clinical trial that combined data from patients who were enrolled in one conventional randomized trial (ACTIV ...

A new method to analyse the blood thinning drug Heparin has been developed that can pinpoint contaminants more accurately and quickly, providing greater quality control and safety. A new method to ...